Clinical advances in obsessive-compulsive disorder: a position statement by the International College of Obsessive-Compulsive Spectrum Disorders
- PMID: 32433254
- PMCID: PMC7255490
- DOI: 10.1097/YIC.0000000000000314
Clinical advances in obsessive-compulsive disorder: a position statement by the International College of Obsessive-Compulsive Spectrum Disorders
Abstract
In this position statement, developed by The International College of Obsessive-Compulsive Spectrum Disorders, a group of international experts responds to recent developments in the evidence-based management of obsessive-compulsive disorder (OCD). The article presents those selected therapeutic advances judged to be of utmost relevance to the treatment of OCD, based on new and emerging evidence from clinical and translational science. Areas covered include refinement in the methods of clinical assessment, the importance of early intervention based on new staging models and the need to provide sustained well-being involving effective relapse prevention. The relative benefits of psychological, pharmacological and somatic treatments are reviewed and novel treatment strategies for difficult to treat OCD, including neurostimulation, as well as new areas for research such as problematic internet use, novel digital interventions, immunological therapies, pharmacogenetics and novel forms of psychotherapy are discussed.
Conflict of interest statement
N.A.F. declares that in the past 3 years, she had held research or networking grants from the ECNP, UK NIHR, EU H2020, MRC, University of Hertfordshire. In the past 3 years, she had either accepted travel or hospitality expenses or both from the BAP, ECNP, RCPsych, CINP, International Forum of Mood and Anxiety Disorders, World Psychiatric Association and Indian Association for Biological Psychiatry. In the past 3 years, she had received payment from Taylor and Francis and Elsevier for editorial duties. In the past 3 years, she had accepted a paid speaking engagement in a webinar sponsored by Abbott. Previously, she had accepted paid speaking engagements in various industry supported symposia and have recruited patients for various industry-sponsored studies in the field of OCD treatment. She leads an NHS treatment service for OCD. She holds Board membership for various registered charities linked to OCD. She gives expert advice on psychopharmacology to the UK MHRA and NICE. S.W. has received royalties from Thieme, Hogrefe, Kohlhammer, Springer, Beltz in the last 5 years. Her work was supported by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Müller Stiftung, Olga Mayenfisch, Gertrud Thalmann and Vontobel Fonds in the last 5 years. She received no honoraria from pharmaceutical or other industrial companies in the last 36 months. Outside professional activities and interests are declared under the link of the University of Zurich,
Similar articles
-
Functional interventions as augmentation strategies for obsessive-compulsive disorder (OCD): scoping review and expert survey from the international college of obsessive-compulsive spectrum disorders (ICOCS).Int J Psychiatry Clin Pract. 2022 Mar;26(1):92-107. doi: 10.1080/13651501.2021.1872646. Epub 2021 Jan 27. Int J Psychiatry Clin Pract. 2022. PMID: 33502269 Review.
-
Evidence-based treatment for pediatric obsessive-compulsive disorder.Isr J Psychiatry Relat Sci. 2011;48(4):280-7. Isr J Psychiatry Relat Sci. 2011. PMID: 22572092 Review.
-
The influence of age at onset and duration of illness on long-term outcome in patients with obsessive-compulsive disorder: a report from the International College of Obsessive Compulsive Spectrum Disorders (ICOCS).Eur Neuropsychopharmacol. 2013 Aug;23(8):865-71. doi: 10.1016/j.euroneuro.2013.05.004. Epub 2013 Jun 21. Eur Neuropsychopharmacol. 2013. PMID: 23791074
-
Early intervention for obsessive compulsive disorder: An expert consensus statement.Eur Neuropsychopharmacol. 2019 Apr;29(4):549-565. doi: 10.1016/j.euroneuro.2019.02.002. Epub 2019 Feb 14. Eur Neuropsychopharmacol. 2019. PMID: 30773387
-
The Psychopharmacology of Obsessive-Compulsive Disorder: A Preclinical Roadmap.Pharmacol Rev. 2020 Jan;72(1):80-151. doi: 10.1124/pr.119.017772. Pharmacol Rev. 2020. PMID: 31826934 Review.
Cited by
-
5-HT 2A and 5-HT 2C receptor antagonism differentially modulate reinforcement learning and cognitive flexibility: behavioural and computational evidence.Psychopharmacology (Berl). 2024 Aug;241(8):1631-1644. doi: 10.1007/s00213-024-06586-w. Epub 2024 Apr 10. Psychopharmacology (Berl). 2024. PMID: 38594515 Free PMC article.
-
Identifying emotional components of event-related potentials in the brain functioning of individuals with contamination obsessions and comparison with healthy control group.Front Psychol. 2023 Nov 16;14:1240493. doi: 10.3389/fpsyg.2023.1240493. eCollection 2023. Front Psychol. 2023. PMID: 38046120 Free PMC article.
-
Effectiveness of Neuropsychoeducation, Intrinsic Motivation, and Metaphoric Content Integrated with Cognitive Behavioral Therapy in the Treatment of Obsessive-Compulsive Disorder: A Pilot Study.Ann Neurosci. 2023 Oct;30(4):230-235. doi: 10.1177/09727531231160356. Epub 2023 Apr 6. Ann Neurosci. 2023. PMID: 38020398 Free PMC article.
-
Mapping the neuroanatomical abnormalities in a phenotype of male compulsive rats.Behav Brain Funct. 2023 Nov 6;19(1):19. doi: 10.1186/s12993-023-00221-y. Behav Brain Funct. 2023. PMID: 37932782 Free PMC article.
-
Brazilian research consortium on obsessive-compulsive spectrum disorders guidelines for the treatment of adult obsessive-compulsive disorder. Part II: Cognitive-Behavior Therapy treatment.Braz J Psychiatry. 2023 Sep 17;45(5):431-47. doi: 10.47626/1516-4446-2023-3081. Online ahead of print. Braz J Psychiatry. 2023. PMID: 37718254 Free PMC article.
References
-
- Abdolhosseinzadeh S, Alizadeh N, Shams J, Asadi S, Ahmadiani A. BDNF association study with obsessive-compulsive disorder, its clinical characteristics, and response to fluvoxamine-treatment in Iranian patients. 2019a; 28:216–224 - PubMed
-
- Abdolhosseinzadeh S, Sina M, Ahmadiani A, Asadi S, Shams J. Genetic and pharmacogenetic study of glutamate transporter (SLC1A1) in Iranian patients with obsessive-compulsive disorder. J Clin Pharm Ther. 2019b; 44:39–48 - PubMed
-
- Aboujaoude E, Barry JJ, Gamel N. Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. J Clin Psychopharmacol. 2009; 29:51–55 - PubMed
-
- Abramowitz JS. The psychological treatment of obsessive – compulsive disorder. can. J Psychiatry. 2006; 51:407–416 - PubMed
-
- Ackerman DL, Greenland S. Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder. J Clin Psychopharmacol. 2002; 22:309–317 - PubMed